Our results demonstrated that ovarian cancer cells with elevated PABPC3 expression exhibited decreased drug sensitivity to chemotherapeutic agents and decreased sensitivity to PARP inhibitors. This evidence concerns the gene PABPC3 and ovarian carcinoma.